Regulation in Infection Biology

Understanding the pathophysiological events and processes during the onset and progression of infectious diseases is elementary to the development of novel and highly innovative, targeted therapeutics. These therapeutics or anti-infectives can either target critical components of the infective agent, bacteria or viruses, or directly interfere with host (human) innate immune responses and pathways. The team is particularly interested in deciphering how bacterial RNAs and proteins succeed to orchestrate and fine-modulate gene expression at the transcriptional, post-transcriptional and post-translational level. A better insight into these critical regulatory mechanisms could potentially allow for the development of target tailored therapies. A successful example of potential application of our research in biotechnology and medicine is our recent discovery of an RNA programmable genome editing tool (dual-RNA guided DNA cleavage enzyme Cas9) that stems from our analysis of the adaptive immune CRISPR-Cas system in bacterial pathogens.

Emmanuelle Charpentier's Department is affiliated to the Laboratory for Molecular Infection Medicine Sweden (MIMS) at the Department of Molecular biology of Umeå University. The Department is also affiliated to the Hannover Medical School (MHH).

Prof. Dr. Emmanuelle Charpentier

„Our research program focuses on mechanisms of regulation in infection and immunity. We want to understand how RNA and protein molecules work and cooperate to control gene expression and biological processes in bacterial pathogens.“

Emmanuelle Charpentier studied biochemistry and microbiology at the University Pierre and Marie Curie, Paris, France and obtained her PhD in Microbiology for her research performed at the Pasteur Institute. She then continued her work in the United States, at the Rockefeller University, New York University Langone Medical Center and the Skirball Institute of Biomolecular Medicine (all in New York, NY) and at St Jude Children’s Research Hospital (in Memphis, TN). Emmanuelle returned to Europe to establish her own research group at the Max F. Perutz Laboratories of the University of Vienna in Austria where she habilitated in the field of Microbiology. She was then appointed Associate Professor and then Guest Professor at the Laboratory for Molecular Infection Medicine Sweden (MIMS, within the Nordic EMBL Partnership for Molecular Medicine) at Umeå University in Sweden where she habilitated in the field of Medical Microbiology. Since 2013, Emmanuelle is also head of the department “Regulation in Infection Biology” at the Helmholtz Centre for Infection Research, and Professor at the Medial School of Hannover in Germany. The same year, she was awarded an Alexander von Humboldt Professorship, which she has been holding since 2014.


With her recent groundbreaking findings in the field of RNA-mediated regulation based on the CRISPR-Cas9 system, Emmanuelle has laid the foundation for the development of a novel, highly versatile and specific genome editing tool that is revolutionizing life sciences research and could open up whole new opportunities in biomedical gene therapies. Emmanuelle has been awarded prestigious honors including the Breakthrough Prize in Life Sciences, the Louis Jeantet Prize for Medicine, an Alexander von Humboldt Professorship, the Dr Paul Janssen Award, an EMBO Membership, Le Grand Prix Jean-Pierre LeCocq, the Ernst-Jung Prize for Medicine, the Göran Gustafsson Prize and the Eric K. Fernström Prize. Emmanuelle is scientific founder of CRISPR Therapeutics and ERS Genomics.


  • Prof Dr Emmanuelle Charpentier

    Emmanuelle Charpentier

    Head of the Department Regulation in Infection Biology

    +49 531 6181-5500



Are you interested in joining our research group?

We are constantly looking for highly motivated and enthusiastic bachelor and master students, PhD students and Post-docs who would like to join our team. Please contact directly Emmanuelle Charpentier for more information. The Department is a host lab for Alexander von Humboldt fellows: please have a look at the website We are looking forward to your application!